Abstract
Lipid control is crucial in managing coronary artery disease (CAD) to reduce cardiovascular risk. This study aimed to evaluate the effectiveness of lipid-lowering therapy, particularly statins, in achieving target lipid levels in patients with CAD. This single-center, retrospective, observational study was conducted at the Cardiology Outpatient Department of Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, Maharastra, India. A sample size of 72 patients was included in this study. Adult patients receiving treatment for acute coronary syndrome (ACS), chronic stable angina (CSA), or unstable angina (UA) were included. Exclusion criteria were comorbidities affecting clinical decisions, HIV-positive status, pregnancy, or breastfeeding. Data on lipid profiles, including low-density lipoprotein (LDL) cholesterol (LDL-C), were collected, with LDL-C calculated using the Friedewald equation or measured directly. The primary outcome was the proportion of patients achieving LDL-C targets as per the 2019European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Statistical analysis was performed using chi-square tests, with significance set at p < 0.05. Of the enrolled patients, a substantial proportion did not achieve target LDL-C levels, with LDL-C remaining above the recommended thresholds in a significant number of patients. Despite ongoing statin therapy, lipid control was suboptimal in many cases, particularly among those with elevated LDL-C levels. A detailed analysis of lipid profiles and the achievement of target levels was done, highlighting areas where current treatment strategies may fall short. The study reveals that a significant number of patients with CAD on statin therapy do not achieve optimal lipid control, particularly in LDL-C management. This underscores the need for more aggressive or tailored lipid-lowering strategies to reduce residual cardiovascular risk in this high-risk population. Further studies are needed to explore the factors contributing to suboptimal lipid control and to develop interventions that can enhance the effectiveness of current therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
